Patent cliffs don't have to mean revenue cliffs. For respiratory firms facing generic competition, the real differentiator lies beyond the molecule — in the patient experience itself. This case study explores how QUANTUM helped a leading respiratory company design and launch a connected therapy ecosystem that improved adherence by 25%, generated a new subscription revenue stream, and repositioned the firm as a Digital Health player in the eyes of financial analysts.

How a Connected Therapy Ecosystem Solved the Respiratory Adherence Crisis — and Unlocked a New Revenue Stream

The Challenge

A leading respiratory firm was facing the patent cliff for their flagship inhaler. They needed to differentiate their "generic-plus" replacement. Their biggest hurdle was patient adherence: over 50% of patients used the device incorrectly or inconsistently, leading to poor clinical outcomes and frequent emergency room visits.

The Solution

The QUANTUM Solution: We helped them design and launch a "Connected Therapy" Ecosystem.

• • Smart Inhaler Integration: We developed a companion app that synced via Bluetooth to the device, providing real-time feedback on "Inhalation Quality" to the patient.
  • Tiered Digital Services: We implemented a "Professional" tier for clinicians, providing them with an automated "At-Risk Patient" list based on low adherence data.
  • Behavioral Gamification: Using Visconti-informed behavioral triggers, the app rewarded patients for consistent, correct usage, turning a chore into a habit.
    
    

The Impact

• 25% Improvement in Adherence: Clinically proven increase in correct daily usage over 12 months.

• • New Revenue Stream: The firm successfully monetized the "Professional Dashboard" as a subscription service for large hospital networks.
  • Valuation Multiplier: The firm was re-rated by analysts as a "MedTech/Digital Health" player rather than just a pharmaceutical company, increasing their P/E ratio.